Search

  1. ProQR update and additional sepofarsen Illuminate trial analyses

    News update

    ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.

    ProQR logo on the left. The word update on the right.

  3. ProQR at TIDES to highlight our Axiomer® technology

    Blog

    … ProQR at TIDES to highlight our Axiomer® technology This month several ProQRians will attend the Oligonucleotide and Peptide … beyond. At this year’s TIDES Europe, Gerard Platenburg, ProQR Chief Scientific Officer, and co-founder, is presenting …

    Two ProQRians standing outside TIDES EU 2022 Conference Entrance

  4. Today marks an expansion of the ProQR and Lilly partnership

    News update

    … Today marks an expansion of the ProQR and Lilly partnership In September 2021 ProQR announced a global licensing and research collaboration … originally announced in September 2021 , applied ProQR’s proprietary Axiomer® RNA editing platform to target …

    Axiomer partnership

  6. ProQR Top-line results Phase 1/2 trial of sepofarsen in LCA10 patients

    Webcast

    … ProQR Top-line results Phase 1/2 trial of sepofarsen in LCA10 patients ProQR presents Positive Top-Line Results from the Phase 1/2 … link . Thu, 10/10/2019 - 08:00 - Thu, 10/10/2019 - 09:00 ProQR presents Positive Top-Line Results from the Phase 1/2 …